PFE250509P29000
- 6.51
- +0.11+1.72%
Pfizer Newsroom
Argus Research Maintains Pfizer(PFE.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Personalis (PSNL) and Omnicell (OMCL)
Leerink Partners Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $26
Hold Rating on Pfizer Amid Political Challenges in Biopharmaceutical Sector
BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $30
Pfizer Analyst Ratings
BofA Securities Adjusts Price Target on Pfizer to $27 From $26, Maintains Neutral Rating
UBS Adjusts Price Target on Pfizer to $25 From $24, Maintains Neutral Rating
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $24 to $32
Pfizer Positioned for Growth: Buy Rating Affirmed Due to Operational Efficiency, Strategic Capital Allocation, and Undervaluation
Citigroup Adjusts Price Target on Pfizer to $25 From $23, Maintains Neutral Rating
Goldman Sachs Ups Price Target on Pfizer to $27 From $25, Maintains Neutral Rating
Morgan Stanley Lifts Price Target on Pfizer to $32 From $31, Keeps Equalweight Rating
Pfizer's Mixed Q1 Results and Uncertain Long-Term Prospects Justify Hold Rating
Jefferies Reaffirms Their Buy Rating on Pfizer (PFE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE) and Nautilus Biotechnolgy (NAUT)
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Phathom Pharmaceuticals (PHAT) and Exact Sciences (EXAS)
Research Alert: Solid Q1 Eps Beat, While Revenue Slightly Disappoints; 2025 Guidance Maintained
Pfizer's Financial Outlook: Hold Rating Amidst Short-Term Challenges and Long-Term Potential
Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $28